Geneva, Switzerland

Terry Finn

This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Debiopharm International, S.a.. Active years: 2025-2026.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 5.8

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Terry Finn - Innovator in Antibacterial Compounds

Introduction

Terry Finn is a notable inventor based in Geneva, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibacterial compounds. His work focuses on creating effective solutions to combat bacterial infections.

Latest Patents

Terry Finn holds a patent for "Compounds and their use." This invention provides compounds of the general formula (I) or pharmaceutically acceptable prodrugs, salts, and/or solvates thereof. The compounds exhibit antibacterial activity against both Gram-negative and Gram-positive bacteria. The patent also covers pharmaceutical compositions containing these compounds, their therapeutic uses, and methods for manufacturing them.

Career Highlights

Terry Finn is currently employed at Debiopharm International S.A., where he continues to innovate in the pharmaceutical industry. His work has been instrumental in advancing antibacterial treatments, showcasing his commitment to improving public health.

Collaborations

Terry collaborates with Juan Bravo, contributing to the development of new pharmaceutical solutions. Their partnership exemplifies the importance of teamwork in the field of research and innovation.

Conclusion

Terry Finn's contributions to antibacterial compounds highlight his role as a key inventor in the pharmaceutical industry. His innovative work continues to pave the way for new treatments against bacterial infections.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…